Nova Nazare

Researchers are evaluating a new parenting program aimed at helping parents manage common behavioral challenges faced by children during daily transitions. This feasibility study focuses on children aged 4 to 10 years who show difficulties in managing everyday routines, especially those with behaviors consistent with ADHD, though diagnosis is not required. The study aims to assess the practical use and preliminary effects of delivering parenting education through automated video and text messages. Parents participating in the study will receive a series of six short educational videos via a popular texting platform, delivered approximately every three days. Along with the videos, parents will get daily text messages that include tips for applying the strategies and assessments of their childs transition behaviors. The program emphasizes behavior management techniques based on antecedent and reinforcement strategies to build positive parenting habits. Participants will be asked to engage with the videos and respond to daily ratings over one month. Researchers will evaluate program usability, satisfaction, and the impact on parenting practices and child behavior through questionnaires and parent reports. The primary outcomes include the number of videos viewed, completion rates of daily ratings, and participant satisfaction within one month. Secondary outcomes assess child difficulties with transitions, parenting consistency, use of physical control, hostility, and parent stress. The total participation time is one month.

Researchers are investigating how well the drug VITRAKVI generic name larotrectinib works and how well patients tolerate it in real-world use for those with TRK fusion cancer. This cancer type involves a genetic change called an NTRK gene fusion that can cause tumors to grow. The study includes adults and children with locally advanced or metastatic solid tumors that have this specific gene fusion, reflecting a variety of common and rare cancers. Patients enrolled in this observational study are those for whom their doctors have decided to treat with larotrectinib. Treatments and medical care follow local standard practices without interference from the study. Participants are grouped based on cancer types like gastrointestinal, head and neck, soft tissue sarcoma, CNS, lung, melanoma, pediatric tumors, and others. Data on treatments, other medications, disease changes, and health symptoms will be collected during routine care. Participants will be observed for 24 to 60 months. Researchers will collect information on treatment side effects up to 30 days after treatment ends and monitor responses, disease control, survival, doses, and developmental milestones for up to 8 years. Medical records, including height, weight, neurological assessments, and Tanner stage will be reviewed as part of this long-term observation.